HOTAIRM1: A Drug Target / Disease Biomarker (G100506311)

Target Name: HOTAIRM1

NCBI ID: G100506311

HOTAIRM1

HOTAIRM1: A Drug Target / Disease Biomarker

Hotairm1 (hotairm1) is a protein that is expressed in the brain and is involved in the regulation of heat production. It is a key player in the heat shock response, which is a critical stress response that helps the body adapt to heat or cold temperatures. The hotairm1 gene has been identified as a potential drug target (or biomarker) for several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

The hotairm1 gene was first identified in the brain using RNA interference technology. The RNA interference technology allows researchers to introduce small interfering RNA (siRNA) into the brain and disrupt the normal expression of specific genes. By using this technology, researchers were able to identify hotairm1 as a gene that was expressed in the brain and was involved in the regulation of heat production.

Hotairm1 is a protein that is composed of 21 amino acids and has a calculated molecular weight of 2.3 kDa. It is expressed in the brain and is involved in the regulation of heat production. The hotairm1 gene is highly conserved, with only a small number of amino acid differences between it and other genes. This suggests that hotairm1 is a highly stable protein and is involved in a critical process in the brain.

The hotairm1 gene is involved in the heat shock response, which is a critical stress response that helps the body adapt to heat or cold temperatures. During the heat shock response, the body produces heat in order to increase its temperature and protect its cells from damage. This process is regulated by a complex network of genes, including hotairm1.

Hotairm1 is a key player in the heat shock response because it is involved in the production of reactive oxygen species (ROS), which can damage cells and contribute to the development of neurodegenerative disorders. ROS are generated by processes that are triggered by stress, including heat stress.

Studies have shown that hotairm1 is involved in the production of ROS during the heat shock response. This suggests that hotairm1 may be a potential drug target (or biomarker) for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Hotairm1 is also involved in the regulation of ion channels, which are responsible for the flow of electrical signals in cells. This suggests that hotairm1 may be involved in the development of some types of cancer. Ion channels are often disrupted in cancer cells, which allows them to grow and spread more easily.

In addition to its involvement in the heat shock response and ion channels, hotairm1 is also involved in the regulation of cell survival. This suggests that hotairm1 may be involved in the development and progression of some types of cancer.

The hotairm1 gene has also been shown to be involved in the regulation of pain perception. This suggests that hotairm1 may be a potential drug target (or biomarker) for chronic pain conditions, such as osteoarthritis and chronic pain.

In conclusion, hotairm1 is a protein that is expressed in the brain and is involved in the regulation of heat production. It is a key player in the heat shock response and is involved in the production of ROS, which can damage cells and contribute to the development of neurodegenerative disorders. Hotairm1 is also involved in the regulation of ion channels and cell survival, and has been shown to be involved in the regulation of pain perception. These properties make hotairm1 a potential drug target (or biomarker) for several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Further research is needed to fully understand the role of hotairm1 in the development and progression of these diseases.

Protein Name: HOXA Transcript Antisense RNA, Myeloid-specific 1

The "HOTAIRM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOTAIRM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets